Table 2.
Assessment of diagnostic value for gastric mucosal lesions based on CLE in the two groups
| Sensitivity (%,(CI)) | Specificity (%,(CI)) | PPV (%,(CI)) | NPV (%,(CI)) | κvalue | |
|---|---|---|---|---|---|
| Normal mucosa or benign inflammatory lesions | |||||
| The sedated group | 64.29(44.11 to 80.69) | 95.92(89.28 to 98.68) | 81.82(58.99 to 94.01) | 90.38(82.62 to 95.04) | 0.65 |
| The un-sedated group |
34.48(18.60 to 54.34) (18.60 to 54.33) |
90.14(80.16 to 95.61) | 58.82(33.45 to 80.57) | 77.11(66.34 to 85.32) | 0.28 |
| IM | |||||
| The sedated group | 85.55(72.78 to 93.07) | 80.28(68.80 to 88.43) | 77.05(64.20 to 86.46) | 87.77(76.64 to 94.16) | 0.65 |
| The un-sedated group | 50.00(33.22 to 66.78) | 68.75(55.80 to 79.43) | 47.37(31.31 to 63.95) | 70.97(57.87 to 81.45) | 0.19 |
| IN | |||||
| The sedated group | 65.11(49.01 to 78.55) | 92.78(84.35 to 97.03) | 82.35(64.83 to 92.61) | 83.70(74.21 to 90.29) | 0.61 |
| The un-sedated group | 40.00(24.35 to 57.79) | 75.39(62.87 to 84.87) | 46.67(28.80 to 65.36) | 70.00(57.71 to 80.07) | 0.16 |
| IN + EGC | |||||
| The sedated group | 86.05(71.37 to 94.20) | 92.77(84.35 to 97.03) | 86.05(71.37 to 94.20) | 92.77(84.35 to 97.03) | 0.79 |
| The un-sedated group | 77.14(59.45 to 88.96) | 72.31(59.61 to 82.35) | 60.00(44.37 to 73.94) | 85.46(72.78 to 93.07) | 0.46 |
| EGC | |||||
| The sedated group | 100(75.93 to 100) | 94.55(88.02 to 97.76) | 72.73(49.56 to 88.39) | 100(95.56 to 100) | 0.82 |
| The un-sedated group | 88.89(63.93 to 68.05) | 87.80(78.27 to 93.68) | 61.54(40.73 to 79.09) | 97.30(89.69 to 99.53) | 0.65 |
IM Intestinal metaplasia; IN Intraepithelial neoplasia; EGC Early gastric cancer